Circulating levels of non-phosphorylated undercarboxylated matrix Gla protein are associated with disease severity in patients with chronic heart failure

Clinical Science

Volumn 121, Issue 3, 2011, Pages 119-127

  Ueland, Thor ^a,b   Dahl, Christen P ^a,b   Gullestad, Lars ^b   Aakhus, Svend ^b   Broch, Kaspar ^b   Skårdal, Rita ^b   Vermeer, Cees ^c,d   Aukrust, Pål ^a,b,e   Schurgers, Leon J ^c,d  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c VitaK Inc   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e UNIVERSITY OF OSLO   (Norway)

Author keywords

All cause mortality; Calcification; Chronic heart failure; Left ventricular function; Matrix carboxylated glutamate protein (MGP)

Indexed keywords

(GAMMA CARBOXYLATED GLUTAMATE) PROTEIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CELL PROTEIN; NEUROHORMONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC DYSFUNCTION; DISEASE COURSE; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; HEART DISEASE; HEART FAILURE; HEART MUSCLE; HEMODYNAMICS; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SYSTOLIC DYSFUNCTION;

ADULT; AGED; CALCINOSIS; CALCIUM-BINDING PROTEINS; CHRONIC DISEASE; DISEASE PROGRESSION; ECHOCARDIOGRAPHY; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PHOSPHORYLATION; REGRESSION ANALYSIS; VENTRICULAR FUNCTION, LEFT;

EID: 79955602383     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20100589     Document Type: Article

References (27)

1. Jane-Lise, S., Corda, S., Chassagne, C. and Rappaport, L. (2000) The extracellular matrix and the cytoskeleton in heart hypertrophy and failure. Heart Failure Rev. 5, 239-250.
2. Miner, E. C. and Miller, W. L. (2006) A look between the cardiomyocytes: the extracellular matrix in heart failure. Mayo Clin. Proc. 81, 71-76.
3. Bostrom, K. (2001) Insights into the mechanism of vascular calcification. Am. J. Cardiol. 88, 20E-22E.
4. Vermeer, C. (1990) γ-Carboxyglutamate-containing proteins and the vitamin K-dependent carboxylase. Biochem. J. 266, 625-636.
5. Nishimoto, S. K. and Nishimoto, M. (2005) Matrix Gla protein C-terminal region binds to vitronectin. Co-localization suggests binding occurs during tissue development. Matrix Biol. 24, 353-361.
6. Danziger, J. (2008) Vitamin K-dependent proteins, warfarin, and vascular calcification. Clin. J. Am. Soc. Nephrol. 3, 1504-1510.
7. Schurgers, L. J., Aebert, H., Vermeer, C., Bultmann, B. and Janzen, J. (2004) Oral anticoagulant treatment: friend or foe in cardiovascular disease? Blood 104, 3231-3232.
8. Price, P. A., Faus, S. A. and Williamson, M. K. (1998) Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler. Thromb. Vasc. Biol. 18, 1400-1407.
9. Hwang, D. M., Dempsey, A. A., Lee, C. Y. and Liew, C. C. (2000) Identification of differentially expressed genes in cardiac hypertrophy by analysis of expressed sequence tags. Genomics 66, 1-14.
10. Weinberg, E. O., Mirotsou, M., Gannon, J., Dzau, V. J., Lee, R. T. and Pratt, R. E. (2003) Sex dependence and temporal dependence of the left ventricular genomic response to pressure overload. Physiol. Genomics 12, 113-127.
11. Mirotsou, M., Dzau, V. J., Pratt, R. E. and Weinberg, E. O. (2006) Physiological genomics of cardiac disease: quantitative relationships between gene expression and left ventricular hypertrophy. Physiol. Genomics 27, 86-94.
12. Rysa, J., Leskinen, H., Ilves, M. and Ruskoaho, H. (2005) Distinct upregulation of extracellular matrix genes in transition from hypertrophy to hypertensive heart failure. Hypertension 45, 927-933.
13. Blaxall, B. C., Spang, R., Rockman, H. A. and Koch, W. J. (2003) Differential myocardial gene expression in the development and rescue of murine heart failure. Physiol. Genomics 15, 105-114.
14. Mustonen, E., Pohjolainen, V., Aro, J., Pikkarainen, S., Leskinen, H., Ruskoaho, H. and Rysa, J. (2009) Upregulation of cardiac matrix Gla protein expression in response to hypertrophic stimuli. Blood Press. 18, 286-293.
15. Ueland, T., Gullestad, L., Dahl, C. P., Aukrust, P., Aakhus, S., Solberg, O. G., Vermeer, C. and Schurgers, L. J. (2010) Undercarboxylated matrix Gla protein is associated with indices of heart failure and mortality in symptomatic aortic stenosis. J. Intern. Med. 268, 483-492.
16. Lang, R. M., Bierig, M., Devereux, R. B., Flachskampf, F. A., Foster, E., Pellikka, P. A., Picard, M. H., Roman, M. J., Seward, J., Shanewise, J. S. et al. (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J. Am. Soc. Echocardiogr. 18, 1440-1463.
17. Appleton, C. P., Hatle, L. K. and Popp, R. L. (1988) Relation of transmitral flow velocity patterns to left ventricular diastolic function: new insights from a combined hemodynamic and Doppler echocardiographic study. J. Am. Coll. Cardiol. 12, 426-440.
18. Nagueh, S. F., Appleton, C. P., Gillebert, T. C., Marino, P. N., Oh, J. K., Smiseth, O. A., Waggoner, A. D., Flachskampf, F. A., Pellikka, P. A. and Evangelista, A. (2009) Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J. Am. Soc. Echocardiogr. 22, 107-133.
19. Schirmer, H., Lunde, P. and Rasmussen, K. (2000) Mitral flow derived Doppler indices of left ventricular diastolic function in a general population; the Tromso study. Eur. Heart J. 21, 1376-1386.
20. Parker, B. D., Schurgers, L. J., Vermeer, C., Schiller, N. B., Whooley, M. A. and Ix, J. H. (2010) The association of uncarboxylated matrix Gla protein with mitral annular calcification differs by diabetes status: The Heart and Soul study. Atherosclerosis 210, 320-325.
21. Schurgers, L. J., Cranenburg, E. C. and Vermeer, C. (2008) Matrix Gla-protein: the calcification inhibitor in need of vitamin K. Thromb. Haemostasis 100, 593-603.
22. Cranenburg, E. C., Koos, R., Schurgers, L. J., Magdeleyns, E. J., Schoonbrood, T. H., Landewe, R. B., Brandenburg, V. M., Bekers, O. and Vermeer, C. (2010) Characterisation and potential diagnostic value of circulating matrix Gla protein (MGP) species. Thromb. Haemostasis 104, 811-822.
23. Luo, G., Ducy, P., McKee, M. D., Pinero, G. J., Loyer, E., Behringer, R. R. and Karsenty, G. (1997) Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386, 78-81.
24. Cario-Toumaniantz, C., Boularan, C., Schurgers, L. J., Heymann, M. F., Le, C. M., Leger, J., Loirand, G. and Pacaud, P. (2007) Identification of differentially expressed genes in human varicose veins: involvement of matrix gla protein in extracellular matrix remodeling. J. Vasc. Res. 44, 444-459.
25. Holland, R., Rechel, B., Stepien, K., Harvey, I. and Brooksby, I. (2010) Patients' self-assessed functional status in heart failure by New York Heart Association class: a prognostic predictor of hospitalizations, quality of life and death. J. Card. Failure 16, 150-156.
26. Kallistratos, M. S., Dritsas, A., Laoutaris, I. D. and Cokkinos, D. V. (2008) Incremental value of N-terminal pro-brain natriuretic peptide over left ventricle ejection fraction and aerobic capacity for estimating prognosis in heart failure patients. J. Heart Lung Transplant. 27, 1251-1256.
27. Neuhold, S., Huelsmann, M., Strunk, G., Stoiser, B., Struck, J., Morgenthaler, N. G., Bergmann, A., Moertl, D., Berger, R. and Pacher, R. (2008) Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J. Am. Coll. Cardiol. 52, 266-272.